NeOnc Reports Tumor Remission Data and Advances Brain Cancer Treatment Platform

Apr 16, 2026

NeOnc is reporting promising clinical progress with its NEO-100 therapy, showing tumor remission in 24% of patients with recurrent glioblastoma—significantly higher than current standard-of-care outcomes. The company is awaiting full Phase 2a data readout in the coming months as it advances its brain cancer treatment platform.

Using a proprietary intranasal delivery system that bypasses the blood-brain barrier, NeOnc aims to improve drug delivery while reducing toxicity. With additional therapies in development and plans for global clinical expansion, the company is positioning its platform as a potential breakthrough in treating aggressive brain cancers.

#NeOnc
#BrainCancer
#Glioblastoma
#Biotech
#ClinicalTrials
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Oncology
#Neuroscience
#Pharmaceuticals
#BiotechInvesting
#Innovation
#Healthcare
#NewsOut